Auris Medical's Second Phase III Tinnitus Trial Disappoints

Auris Medical Holding's investigational tinnitus product, Keyzilen, has failed to meet its primary efficacy endpoint in an interim analysis of a second Phase III trial, adding to a series of clinical disappointments over the past few years for the Swiss biotech.